Ran Frenkel, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 2,046 shares at $15.52 ($32K) on 2021-02-11, disclosed to the SEC on 2021-02-17.
Open-market sale of $32k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KPTI | SELL | 2022-02-09 | $20K | — | Filing → |
| KPTI | SELL | 2021-02-22 | $43K | — | Filing → |
| KPTI | SELL | 2020-05-11 | $39K | — | Filing → |